A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes (Q34022647)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes |
scientific article |
Statements
1 reference
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes (English)
1 reference
M S Kipnes
1 reference
P Hollander
1 reference
K Fujioka
1 reference
I Gantz
1 reference
T Seck
1 reference
N Erondu
1 reference
Y Shentu
1 reference
K Lu
1 reference
S Suryawanshi
1 reference
M Chou
1 reference
A O Johnson-Levonas
1 reference
S B Heymsfield
1 reference
D Shapiro
1 reference
K D Kaufman
1 reference
J M Amatruda
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference